

IN THE CLAIMS

1. (currently amended) A kit useful for sequential administration in anticancer therapy, comprising:

- a. oxaliplatin,
- b. injectable calcium,
- c. injectable magnesium, and
- d. calcium in oral administration form;

wherein the injectable calcium and calcium in oral administration form are separate compositions, and wherein the oral calcium is in the form of a capsule or tablet.

2. (cancelled)

3. (cancelled)

4. (previously presented) The kit of claim 1, wherein both the injectable calcium and calcium in oral administration form are separately present as a gluconate, bromogalactogluconate, gluconolactate or carbonate salt, and the injectable magnesium is present as a sulfate or pidolate salt.

5. (previously presented) The kit of claim 4, wherein the cation of said injectable calcium salt is present in a concentration between 8 and 20 mg/ml, and wherein the cation of said injectable magnesium salt is present in a concentration between 10 and 20 mg/ml, the concentrations being expressed as calcium or magnesium ions, respectively.

6. (currently amended) A method of inhibiting or treating neurotoxicity caused by the administration of oxaliplatin, comprising: (a) administering by injection to a patient both prior to and after administration of oxaliplatin of about 2 to about 3 at least 1-g calcium and about 2 to about 3 at least 1-g of magnesium effective to inhibit or treat the neurotoxicity, and (b) administering calcium by the oral route in the form of a capsule or

| tablet as a gluconate, chloride, bromogalactogluconate, gluconolactate or carbonate salt following the treatment with oxaliplatin.

7. (cancelled)

8. (cancelled)

9. (cancelled)

10. (cancelled)

11. (previously presented) The method of claim 6, wherein said calcium and magnesium administered by injection to the patient are administered separately.

12. (previously presented) The kit of claim 5, wherein the concentration of said injectable magnesium salt is 15 mg/ml.

| 13. (currently amended) The method of claim 6, wherein the calcium administered by the oral route is administered at a dose of about 1 to about 2 ~~at least 1~~ g/day.

14. (previously presented) The method of claim 13, wherein the calcium administered by the oral route following treatment with oxaliplatin is administered for 8 days after treatment with oxaliplatin.